BRAF and metastatic malignant neoplasm in the lymph nodes: Other research (20) showed that HT was related to less lymph node metastasis and extrathyroidal extension in PTCs with the BRAF V600E mutation and may play a protective factor in PTCs by directly or indirectly inhibiting the expression of the BRAF V600E mutation and reducing the presence of the aggressive factors in PTCs with BRAF V600E mutation.